Bristol-Myers Squibb announces global collaboration with leading academic institutions

Bristol-Myers SquibbBristol-Myers Squibb Company (NYSE: BMY) announced the formation of the International Immuno-Oncology Network (II-ON), a global collaboration between industry and academia that aims to further the scientific understanding of immuno-oncology. Immuno-oncology focuses on the potential of harnessing the intelligence of the body's own immune system to fight cancer. In addition to Bristol-Myers Squibb, the II-ON is currently comprised of ten leading cancer-research institutions, including:
  • Clinica Universidad Navarra, Pamplona, Spain
  • Dana-Farber Cancer Institute, Boston, MA
  • The Earle A. Chiles Research Institute (Providence Health & Services), Portland, OR
  • Institut Gustave Roussy, Villejuif, France
  • Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale,” Naples, Italy
  • Johns Hopkins Kimmel Cancer Center, Baltimore MD
  • Memorial Sloan-Kettering Cancer Center, New York, NY
  • The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK
  • The Netherlands Cancer Institute, Amsterdam, NL
  • The University of Chicago, Chicago, IL

An objective of this collaborative forum is to facilitate the translation of scientific research findings into clinical trials and, eventually, clinical practice. It will also work to further advance innovation in drug discovery and development.

"The International Immuno-Oncology Network facilitates a public-private partnership that will leverage intellectual capabilities across a global network," said Elliott Sigal, M.D., Ph.D., executive vice president, chief scientific officer and president, Research and Development, Bristol-Myers Squibb. "The shared commitment of all those participating in this collaboration is to evolve our understanding of immuno-oncology towards our ultimate goal of improving patient outcomes."

The role of immuno-oncology in cancer research is growing and in 2011 the concept of "evading immune destruction" was added to the "Hallmarks of Cancer," a widely-referenced peer-reviewed article outlining traits that are believed to be the underlying principles of cancer.

Immuno-Oncology at Bristol-Myers Squibb
The substantial potential of the immune system's intrinsic ability to fight cancer is fundamental to immuno-oncology research at Bristol-Myers Squibb and its ongoing commitment to advancing cancer care. The company is exploring a variety of compounds and immunotherapeutic approaches for patients with different types of cancer, and the formation of the II-ON is an important example of the company's commitment to this area of research.

About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Most Popular Now

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

Time-restricted eating reshapes gene expression th…

Numerous studies have shown health benefits of time-restricted eating including increase in life span in laboratory studies, making practices like intermittent fasting a ...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...

500,000 missed out on blood pressure lowering drug…

Nearly half a million people missed out on starting medication to lower their blood pressure during the COVID-19 pandemic, according to research supported by the British ...